{"transactions":[{"id":790259,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2026-05-07T00:40:53.000Z","date":"2026-05-04","kind":"other","planned":false,"acquired":true,"shares":2143706,"ownership":{"direct":false,"nature":"See Remarks"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held by GNI USA. GNI Japan may be deemed for purposes of Section 16 of the Exchange Act to be the indirect beneficial owner of the securities held by GNI USA."}],"balance_after":2143706,"derivative":{"underlying":"Common Stock","underlying_shares":10718530},"source":{"system":"sec-edgar","filing":"0001140361-26-019378","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019378/form4.xml","form_type":"4"}},{"id":790258,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2026-05-07T00:40:53.000Z","date":"2026-05-04","kind":"other","planned":false,"acquired":true,"shares":458120,"ownership":{"direct":false,"nature":"See Remarks"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Japan\"). GNI USA, Inc., a Delaware corporation (\"GNI USA\") is a wholly-owned subsidiary of GNI Japan. GNI USA may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), to be the indirect beneficial owner of the securities held by GNI Japan."}],"balance_after":458120,"derivative":{"underlying":"Common Stock","underlying_shares":2290600},"source":{"system":"sec-edgar","filing":"0001140361-26-019378","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019378/form4.xml","form_type":"4"}},{"id":1731640,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-11-23T00:27:22.000Z","date":"2023-10-30","kind":"other","planned":false,"acquired":true,"shares":63588119,"ownership":{"direct":false,"nature":"See Remarks"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the number of shares of common stock of the Issuer received by the Reporting Person in exchange for the shares of Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (\"CPI\") and Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271, held by the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the \"Business Combination Agreement\"), by and among Catalyst Biosciences, Inc., a Delaware corporation,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[cont'd from FN 1] GNI USA, Inc., a Delaware corporation (\"GNI USA\"), the Reporting Person, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and CPI. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by GNI USA which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Japan\"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA."}],"balance_after":64005887,"source":{"system":"sec-edgar","filing":"0001140361-23-054514","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123054514/form4.xml","form_type":"4"}},{"id":1753300,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series X Convertible Preferred Stock Warrant (Right to Buy)","published_at":"2023-11-01T01:56:40.000Z","date":"2023-10-27","kind":"purchase","planned":false,"acquired":true,"shares":8110300,"price":0.125,"value":1013787.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These warrants have an exercise price of $4,915.00 per share of Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by GNI USA, Inc., a Delaware corporation (\"GNI USA\") which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Japan\"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA."}],"balance_after":8110300,"derivative":{"exercise_date":"2023-10-30","expiration_date":"2033-10-30","underlying":"Series X Convertible Preferred Stock","underlying_shares":811},"source":{"system":"sec-edgar","filing":"0001140361-23-050569","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050569/form4.xml","form_type":"4"}},{"id":1753299,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series X Convertible Preferred Stock","published_at":"2023-11-01T01:56:40.000Z","date":"2023-10-27","kind":"purchase","planned":false,"acquired":true,"shares":811,"price":4915,"value":3986065.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the \"Preferred Stock\"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the \"Preferred Stock\"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by GNI USA, Inc., a Delaware corporation (\"GNI USA\") which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Japan\"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA."}],"balance_after":13151,"derivative":{"underlying":"Common Stock","underlying_shares":811000},"source":{"system":"sec-edgar","filing":"0001140361-23-050569","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050569/form4.xml","form_type":"4"}}]}